Comparative Pharmacology
Head-to-head clinical analysis: APHTHASOL versus CORDRAN SP.
Peer-Reviewed Evidence
Head-to-head clinical analysis: APHTHASOL versus CORDRAN SP.
APHTHASOL vs CORDRAN SP
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aphthasol (amlexanox) is an anti-inflammatory agent that inhibits the formation and release of inflammatory mediators such as histamine and leukotrienes from mast cells, neutrophils, and other inflammatory cells. It also inhibits the activation of eosinophils and neutrophils, and reduces cytokine production, thereby suppressing the immune response involved in aphthous ulcer formation.
Topical corticosteroid that induces phospholipase A2 inhibitory proteins (lipocortins), inhibiting arachidonic acid release and subsequent prostaglandin and leukotriene synthesis, thereby mediating anti-inflammatory, antipruritic, and vasoconstrictive effects.
Adults: 5 mg orally three times daily for 5 days.
Apply a thin film to the affected area 1 to 2 times daily. Use the smallest amount for adequate therapy. Do not use for more than 2 weeks per course of treatment.
None Documented
None Documented
Terminal elimination half-life is 1.5 to 2.5 hours. This short half-life supports multiple daily dosing for local therapeutic effect with minimal systemic accumulation.
Terminal half-life approximately 48 hours; prolonged with hepatic impairment.
Renal excretion of unchanged drug and metabolites accounts for approximately 50-60% of the administered dose, with the remainder eliminated via biliary/fecal routes as metabolites and unchanged drug. Biliary excretion constitutes about 20-30%.
Primarily renal as inactive metabolites; <5% unchanged. Minimal biliary/fecal elimination.
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid